Sunday global outlook · U.S.-focused thematic intelligence · Initial paper-tracking phase

Aman's Global Market Intelligence — 2026-09-13

NEUTRAL / EVENT-HEAVY Friday's rebound improved the tape, but a near-5% 10-year yield, $100 oil and a genuinely uncertain Sep. 16 FOMC leave little room for chasing duration.

Generated 08:30:45 CEST (Europe/Rome); data cutoff 08:30 CEST. Sunday mode: all cash prices are Friday Sep. 11 closes; U.S. Treasury par yields are official Sep. 11 observations. Exchange-listed U.S. futures are closed, so Friday settlements are not weekend indications. Monday's Asian/European sessions and many U.S. releases were not yet available at this cutoff.

Executive dashboard

S&P 500 · Sep. 117,656.98+0.86% Fri
−0.80% week
Nasdaq Composite26,333.04+0.96% Fri
−0.66% week
Dow52,573.29+0.98% Fri
−1.57% week
Russell 20002,903.94+0.45% Fri
−2.41% week
VIX15.84−11.21% Fri
+9.02% week
U.S. 2Y / 10Y · Sep. 114.63% / 4.96%+26 / +18 bp vs Sep. 4
Dollar index99.12+0.03% Fri
WTI / Brent$100.05 / $104.61−2.37% / −2.81% Fri
Gold futures$4,408.90+1.02% Fri
Nikkei / Hang Seng64,011 / 24,806−1.93% / −0.60%
Shanghai Composite3,888.11−1.18%
Euro Stoxx 50 / DAX6,325 / 25,569+0.90% / +0.82%
FTSE 10010,650+0.39%
Weekend futuresClosedNo actionable live indication

Index, commodity and thematic closes: Yahoo chart API, cross-checked against CNBC's Friday close report and Reuters' global wrap. Rates: U.S. Treasury primary series. Gold is COMEX front-month close; Reuters' quoted spot level is a different instrument.

1 · FOMC

A live hike decision, not routine event risk

Friday reporting put a 25 bp Sep. 16 hike near 85%–86% after August CPI (+0.4% m/m, +3.4% y/y; core +0.3% m/m). The official meeting is Sep. 15–16 and includes projections. Pricing is not policy guidance. BLS · Fed · Reuters

2 · Oil/geopolitics

The weekly shock persists despite Friday relief

WTI settled $100.05 and Brent $104.61 after both fell roughly 2%–3% Friday, but CNBC reported weekly gains near 10%/9% amid restricted Gulf flows. A verified transit recovery would ease duration pressure; renewed disruption can gap oil and rates. CNBC · Reuters

3 · Breadth

Relief day, damaged week

All major U.S. indices rose Friday and VIX fell, but every tracked U.S. benchmark lost ground for the week; Russell's −2.41% was weakest. Asia fell Friday while Europe rebounded. That is stabilization, not confirmed risk-on breadth. CNBC

Sunday outlook: drivers and scenario map

Macro, central banks, rates and geopolitics

  • Rates: Treasury's newly available Sep. 11 par yields are 4.63% (2Y) and 4.96% (10Y), up 7 bp and 1 bp from Sep. 10 and 26/18 bp from Sep. 4. The curve's front-end move is consistent with a sharply repriced near-term Fed path. Treasury
  • Wednesday collision: retail sales and import/export prices arrive at 14:30 CEST, before the FOMC decision. At 08:30 Italy, none of the coming week's U.S. releases are available. Census · BLS
  • Geopolitics: oil-flow restrictions and Iran/U.S. attacks were the verified Friday narrative. Weekend headlines are gap risk; this report does not infer de-escalation from the Friday oil pullback. Reuters
  • Monday base case: neutral/volatile. Upgrade only if oil and yields fall while broad index breadth follows Friday; downgrade on renewed WTI strength, 10Y above 5% and failed S&P support.

Earnings, regulation, rotation and unusual moves

  • AI rotation: Friday ANET +5.61%, VRT +3.60%, QCOM +2.88% and AMD +2.49% led; NVDA −0.03% and ORCL −1.74% lagged. ANET volume rose to 4.64M from 2.81M Thursday. Price/volume are verified; no unsourced cause is assigned.
  • Oracle reversal: ORCL opened $164.43, reached $166 and closed $150.28 on 79.5M shares after earnings. The filed 10-Q validates the disclosure set, but the tape rejected the gap. SEC 10-Q
  • Primary-filings check: Nvidia's SEC submissions show no new material company filing after its Sep. 3 8-K through the Sunday cutoff; the Sep. 11 entry is a Form 4, not an operating update. SEC submissions JSON
  • Earnings: Nasdaq lists RFIL and HAIN pre-market Sep. 14; neither is a core thematic signal. Later secondary-calendar markers require company-IR confirmation before use. Nasdaq

Theme dashboards

AI · selective

Networking evidence beats indiscriminate beta

  • Leaders/laggards: ANET $199.59 (+5.61%), VRT $257.06 (+3.60%), QCOM $181.97 (+2.88%); NVDA $218.29 (−0.03%), ORCL $150.28 (−1.74%).
  • Verified catalyst: Qualcomm and Amazon announced multi-generation custom AI-inference silicon plus optical connectivity up to 1.6T; commercial economics were not disclosed in the release. Qualcomm
  • Fundamental anchor: Broadcom reported Q3 AI semiconductor revenue of $16.7B (+221% y/y), Q4 AI semiconductor guide $21.7B, and Q3 FCF $13.7B. Broadcom IR
  • Risk: near-5% yields, concentration, export controls, backlog conversion, power/build constraints and valuation. Strong demand does not make every multiple safe.
Quantum · extreme speculation

Funding is real; utility economics remain unproven

  • Friday: QUBT +2.17%, QBTS +0.84%, RGTI +0.73%; IONQ −0.24%. The small moves did not confirm a new group trend.
  • Verified catalyst: Rigetti signed a $100M Commerce agreement targeting readout electronics, cryogenics and fabrication. Funding is milestone/execution dependent and Commerce receives a minority non-controlling equity stake. Rigetti IR
  • Risks: early revenue, burn, dilution, acquisitions, roadmap/fidelity validation, appropriations, liquidity and violent gaps/squeezes. Government funding is not proof of commercial advantage.
Peptide biotech · binary

Viking's Q3 window stays open and undated

  • VKTX closed $31.98 (−0.47%), LLY $1,115.70 (−0.65%) and NVO $43.07 (−2.14%). No fresh weekend clinical result was verified.
  • Viking guides Phase 1 VK2735 maintenance data for Q3. The ~180-person randomized study explores weekly, every-other-week and monthly regimens; safety/tolerability/PK are objectives and weight change is exploratory. Viking IR
  • VANQUISH-1/2 are fully enrolled Phase 3, placebo-controlled 78-week trials with percent body-weight change as the primary endpoint. Prior Phase 2 sponsor-reported mean reduction reached 14.7% after 13 doses; extrapolation is unsafe.
  • Runway/risk: June 30 cash was $502M; shares outstanding rose to 116.65M from 114.79M at year-end and the first-half accumulated loss expansion was material. Binary safety, durability, discontinuation, competition, manufacturing and FDA-path risks dominate.

Ranked conditional ideas — no Sunday fills; levels refer to the next liquid session

Bullish #1Conditional bullish

ANET · Arista Networks (NYSE)

Exchange/risk class: NYSE; large-cap, high-beta AI networking. Classification: relative-strength breakout. Applicable horizon: day trade and 1–4 weeks; long-term only after valuation/fundamental review. Direction: uncertain through FOMC.

Thesis/catalyst/evidence: Friday +5.61% to $199.59 on 4.64M shares versus 2.81M Thursday, outperforming Nasdaq +0.96%; networking demand is corroborated by Broadcom's AI results. Counterargument: one relief day is insufficient, and no new ANET operating release was verified.

Entry/confirmation: close above $200.25 with positive networking/semiconductor breadth; do not chase an opening gap. Invalidation/downside: close below $192.10; $188.99 is next support risk. Key risks: hyperscaler concentration, AI-capex pause, competition, supply, exports, valuation and rates. quote

Thesis Confidence 82
Risk 83
Opportunity 61
Bullish #2Conditional bullish

QCOM · Qualcomm (Nasdaq)

Exchange/risk class: Nasdaq; large-cap semiconductor/customer-catalyst risk. Classification: confirmed watch, not a chase. Applicable horizon: day/1–4 weeks; 3–12+ months only after contract economics emerge. Direction: uncertain.

Thesis/catalyst/evidence: $181.97 close (+2.88%) cleared the prior $180.40 checkpoint; Amazon collaboration covers custom inference silicon and 1.6T optical connectivity. Counterargument: close remained below $183.49 and Friday's $185.46 high; release omitted revenue/margin timing.

Entry/confirmation: close above $185.46, preferably after FOMC. Invalidation/downside: close below $175.74; $172 next risk. Key risks: customer concentration, warrants/dilution, execution, competition, margins, exports and rates. primary release

Thesis Confidence 88
Risk 87
Opportunity 57
Bearish #1Avoid / breakdown confirmation

ORCL · Oracle (NYSE)

Exchange/risk class: NYSE; mega-cap cloud, high capex/debt/event risk. Classification: avoid; bearish only if confirmed. Applicable horizon: day/1–4 weeks, not a structural long-term short. Direction: uncertain; short losses can be unlimited.

Thesis/evidence: Friday's $164.43 gap open failed into $150.28 close on 79.5M shares, below the prior $152.94 invalidation. Counterargument: OCI demand and large RPO can support a violent rebound; backlog is not yet revenue, margin or cash.

Entry/confirmation: bearish only after failed $152.94 reclaim and break below $149.84. Invalidation/downside: bearish case weakens above $159.24; downside below $149.84 is undefined. Key risks: squeeze, debt/credit, concentration, capex, power/construction, conversion and FOMC. Borrow terms unavailable and not assumed. 10-Q

Thesis Confidence 94
Risk 100
Opportunity 52
Bearish #2Avoid / relative weakness

NVO · Novo Nordisk ADR (NYSE)

Exchange/risk class: NYSE ADR; large-cap pharma, FX/pricing/clinical risk. Classification: avoid / breakdown watch. Applicable horizon: 1–4 weeks; no automatic 3–12+ month short. Direction: uncertain.

Thesis/evidence: Friday $43.07 (−2.14%) against S&P +0.86%, below every close last week. Counterargument: established semaglutide franchise and Sep. 29 EASD evidence flow can reverse sentiment; tape is not clinical evidence.

Entry/confirmation: avoid; bearish only on close below $42.72. Invalidation/downside: regain $44.56; stronger above $46.60. Key risks: clinical surprise, access/pricing, supply, patents, FX, competition and squeeze. Borrow availability/fees unknown. Novo/EASD

Thesis Confidence 82
Risk 92
Opportunity 44
Bearish #3Avoid / extreme speculation

IONQ · IonQ (NYSE)

Exchange/risk class: NYSE; high-volatility quantum, acquisition/dilution risk. Classification: bearish trigger needs follow-through. Applicable horizon: day/1–4 weeks only. Direction: uncertain; short losses can be unlimited.

Thesis/evidence: $36.75 close was three cents below the prior $36.78 trigger; 2026 revenue outlook includes acquired SkyWater, limiting direct organic comparison. Counterargument: government awards, roadmap news and integration can drive abrupt squeezes.

Entry/confirmation: bearish only below $36.33 after failed $36.78 reclaim. Invalidation/downside: close above $38.14; downside below $36.33 undefined. Key risks: technical success, contracts, acquisitions, burn, dilution, gaps and liquidity. Borrow terms unknown. IonQ IR

Thesis Confidence 91
Risk 100
Opportunity 38

Watchlist — three evidence checkpoints

AI power/cooling

VRT · Vertiv (NYSE)

Risk/class/horizon/direction: high-beta large-cap; reversal watch; day/1–4 weeks; uncertain. Thesis/catalyst/evidence: +3.60% to $257.06 after two-day drop; AI power/cooling demand is the structural catalyst. Counter: still below $262.89/$263 and −8.37% from Sep. 4. Confirmation: close above $258.78, stronger above $263. Invalidation/downside: below $251.84, then $248.13. Risks: valuation, orders, execution, input/energy costs, rates and whipsaw. quote

Confidence 86
Risk 97
Opportunity 48
Clinical-stage binary

VKTX · Viking Therapeutics (Nasdaq)

Risk/class/horizon/direction: small-cap clinical biotech; event watch; 1–4 weeks around Q3 data and 3–12+ months only after full dataset; uncertain. Thesis/catalyst/evidence: issuer-guided Q3 Phase 1 maintenance readout; ~180 randomized participants; safety/tolerability/PK objectives and exploratory weight change; $502M June cash. Counter: no fixed date, first-half loss/cash burn, share-count growth and limited sample. Confirmation: acceptable safety plus maintained weight and close above $33.05/$33.68. Invalidation/downside: poor durability/safety, delay or close below $31.70. Risks: binary endpoints, GI/discontinuation profile, FDA path, competition, manufacturing and dilution. primary release

Confidence 93
Risk 100
Opportunity 58
Small-cap / quantum

RGTI · Rigetti Computing (Nasdaq)

Risk/class/horizon/direction: small-cap, extreme dilution/technical risk; catalyst watch; day/1–4 weeks only; uncertain. Thesis/catalyst/evidence: signed $100M U.S. agreement addresses concrete electronics, cryogenic and fabrication bottlenecks. Counter: funding depends on execution/milestones; government equity dilutes holders; Friday $15.27 stayed below catalyst-day close. Confirmation: close above $15.81, stronger above $16.40. Invalidation/downside: below $15.08 then $14.84. Risks: dilution, burn, appropriations, fidelity/roadmap, liquidity and gaps. primary release

Confidence 95
Risk 100
Opportunity 43

Scores run 0–100; higher Risk means riskier. Thesis Confidence grades evidence quality, not probability of profit. No Sunday fill or borrow assumption is made.

Changes versus the 2026-09-12 report

  • Regime unchanged: neutral/event-heavy. No cash session occurred and no credible weekend market indication was available by cutoff.
  • Rates updated: official Sep. 11 Treasury data are now available: 2Y 4.63% and 10Y 4.96%, versus the prior report's latest Sep. 10 figures of 4.56%/4.95%. This strengthens, not relaxes, the front-end warning.
  • Gold corrected by instrument clarity: COMEX front-month Friday close is $4,408.90 from Yahoo's chart feed; Friday media spot quotes near $4,350 are not directly interchangeable.
  • No idea status changed: ANET/QCOM remain conditional bullish; ORCL/NVO/IONQ remain avoid/confirmation-only. Friday levels are carried forward rather than fabricated from a closed market.
  • Research update: SEC submissions show no new material Nvidia operating filing after Sep. 3 through cutoff; weekend thematic search found no primary result that overrides Friday's setup.
  • Sunday emphasis: scenario planning replaces Saturday's call audit. The first true price discovery arrives in Asia, then Europe, then U.S. futures.

Important 7–30 day catalysts

Sep. 15 · 14:30 CEST — Empire State Manufacturing
First major U.S. activity checkpoint. NY Fed calendar
Sep. 15–16 — FOMC; decision Sep. 16
Policy decision and Summary of Economic Projections. Friday reporting indicated ~85%–86% odds of 25 bp hike, but only the Fed is authoritative. Federal Reserve · CME
Sep. 16 · 14:30 CEST — Retail sales and import/export prices
August demand and external-price pressure land before the Fed; inventories follow at 16:00. Census · BLS
Sep. 17 · 14:30 CEST — Housing starts, claims and Philadelphia Fed
Growth/rates read-through. Census confirms August housing starts at 08:30 ET. Census
Sep. 18 · 15:15 CEST — Industrial production/capacity utilization
Relevant to cyclicals, power equipment and data-center supply chains. July IP and manufacturing each rose 0.2%; August is the new release. Fed G.17
Sep. 18–30 — FDA/PDUFA cluster
Third-party calendars flag NUVL Sep. 18, RARE Sep. 19, IONS Sep. 22 and BMY Sep. 30. These are not peptide-theme calls and require issuer/FDA reconfirmation before trading. FDA Tracker · FDA meeting calendar
Sep. 21 — Broadcom record date / information checkpoint
Q3 release sets Sep. 21 dividend record date; it is not an earnings event. Q4 AI guide remains the operating read-through. Broadcom IR
Sep. 24–30 — Costco, durable goods and AI-memory markers
Census confirms new-home sales Sep. 24 and durable goods Sep. 25. Secondary earnings calendars mark Costco Sep. 24 and Micron/Jabil Sep. 30; verify on issuer IR. Census · Nasdaq
By Sep. 30 · undated — VKTX maintenance data
Issuer guidance says Q3; no fixed date. Phase 1 safety/tolerability/PK objectives and exploratory weight-change evidence make this binary and interpretation-sensitive. Viking
Sep. 28–Oct. 2 — EASD 2026; Novo symposium Sep. 29
Potential semaglutide/amylin evidence flow; unpublished outcomes are not assumed. Novo/EASD
Sep. 29/30 — IONQ warrants cease trading / expire
Capital-structure flows may distort the tape; terms are filing-defined. SEC 8-K

Bottom line by horizon

Day trade · Monday/Wednesday

Stance: wait for live price discovery; no Sunday position signal. Conditional longs: ANET close >$200.25 and QCOM >$185.46. Confirmation-only bearish levels: ORCL <$149.84 and IONQ <$36.33 after failed reclaims.

Biggest risk: an oil/geopolitical gap and Wednesday Fed whipsaw. Invalidation: S&P close above 7,677 with falling yields/oil upgrades the regime; close below 7,592 with VIX above 17.84 restores risk-off.

1–4 week swing

Stance: selective, smaller and evidence-led through FOMC. Prefer confirmed AI networking/semiconductor relative strength over debt-heavy cloud and pre-profit quantum.

Biggest risk: oil-driven inflation plus a hike/hawkish path. Invalidation: 10Y sustainably below 4.80% and broad indices above Sep. 4 closes improve duration; renewed 10Y above 5% weakens it.

3–12+ month investment

Stance: AI demand evidence is strong, but require revenue conversion, margins, FCF and balance-sheet capacity. Quantum needs independently validated utility/unit economics; peptide biotech needs complete efficacy/safety, regulatory and runway analysis.

Biggest risk: capital-cost shock, concentration, dilution or technical/clinical failure. Invalidation: sustained deterioration in orders, cash generation, roadmap evidence or clinical benefit—not one volatile session.

Data quality, retrieval log and limitations

  • Live research: more than five meaningful retrievals covered Yahoo chart APIs, CNBC and Reuters market reports, official Treasury XML, the Fed FOMC/G.17 pages, BLS and Census calendars, Nasdaq earnings, SEC submissions, and primary releases from Qualcomm, Broadcom, Rigetti and Viking. The Fed calendar was also loaded directly in a browser.
  • Cross-checks: S&P 7,656.98, Nasdaq 26,333.04 and Dow 52,573.29 match Yahoo API and CNBC exactly; WTI $100.05 and Brent $104.61 match CNBC. Reuters independently confirms Friday's direction and a 4.96% 10Y. Treasury's primary feed confirms 2Y/10Y 4.63%/4.96% for Sep. 11.
  • Session integrity: Sunday has no cash session and exchange-listed U.S. futures were closed at cutoff. Friday ES/NQ settlements were retrieved but deliberately not represented as weekend prices.
  • Blocked/retried sources: direct curl-to-parser commands for Treasury and SEC were initially held by the environment's pipe security scan; both were retried successfully with Python HTTPS retrieval. Nvidia IR extraction resolved as a private-network block, so SEC submissions served as the primary alternative. Lilly's attempted news URL returned 404; IonQ's attempted press-release index returned 404/recaptcha, so its known direct issuer release and SEC filing links were retained. NY Fed and CME extraction hit a temporary scraper rate limit; the Fed's official calendar loaded directly, and Reuters/CNBC independently supplied Friday Fed-pricing context.
  • Availability standard: no broad “data unavailable” claim is made. The specific weekend price limitation is structural (markets closed), not a retrieval failure. Nasdaq's dynamic table did not expose the full week, so later earnings are explicitly calendar markers requiring issuer confirmation.
  • No fabrication: no unsupported rating, target, valuation multiple, analyst estimate, borrow availability/fee, unpublished clinical result or guaranteed award economics is asserted. Primary issuer language is distinguished from independent verification.
Risk notice: The initial two weeks are paper-tracking. Research only—not guaranteed, personalized, fiduciary, legal or tax advice. Verify live quotes, liquidity, filings and clinical/regulatory sources before action; shorts can lose more than invested, and gaps can bypass invalidations.